Drug delivery systems have been extensively developed to enhance the therapeutic efficacy of drugs by altering their pharmacokinetics and biodistribution. However, the use of high quantities of drug delivery systems can cause toxicity due to their poor metabolism and elimination. In this study, we developed polysaccharide-based drug delivery systems which exert potent therapeutic effects and could display synergistic therapeutic effects with drug payloads, leading to dose reduction. Cinnamaldehyde, a major component of cinnamon is known to induce anticancer activity by generating ROS (reactive oxygen species). We developed cinnamaldehyde-conjugated maltodextrin (CMD) as a polymeric prodrug of cinnamaldehyde and a drug carrier. Cinnamaldehyde was conjugated to the hydroxyl groups of maltodextrin via acid-cleavable acetal linkages, allowing facile formulation of nanoparticles and drug encapsulation. CMD nanoparticles induced acid-triggered ROS generation to induce apoptotic cell death. Camptothecin (CPT) was used as a model drug to investigate the potential of CMD nanoparticles as a drug carrier and also evaluate the synergistic anticancer effects with CMD nanoparticles. CPT-loaded CMD nanoparticles exhibited significantly higher anticancer activity than empty CMD nanoparticles and CPT alone in the study of mouse xenograft models, demonstrating the synergistic therapeutic effects of CMD with CPT. Taken together, we believe that CMD nanoparticles hold tremendous potential as a polymeric prodrug of cinnamaldehyde and a drug carrier in anticancer therapy.

已经广泛开发了药物递送系统，以通过改变药物的药代动力学和生物分布来增强药物的治疗功效。然而，由于它们的新陈代谢和消除不良，使用大量的药物递送系统会引起毒性。在这项研究中，我们开发了基于多糖的药物递送系统，该系统发挥了强大的治疗作用，并且可以显示与药物有效载荷的协同治疗作用，从而降低了剂量。肉桂醛是肉桂的主要成分，已知会通过产生ROS（活性氧）来诱导抗癌活性。我们开发了肉桂醛共轭麦芽糖糊精（CMD）作为肉桂醛和药物载体的聚合前药。肉桂醛通过酸可裂解的乙缩醛键与麦芽糖糊精的羟基缀合，可以方便地配制纳米颗粒和药物封装。CMD纳米颗粒诱导酸触发的ROS生成，从而诱导凋亡性细胞死亡。喜树碱（CPT）被用作模型药物，以研究CMD纳米颗粒作为药物载体的潜力，并评估与CMD纳米颗粒的协同抗癌作用。在小鼠异种移植模型的研究中，负载CPT的CMD纳米颗粒比单独的空CMD纳米颗粒和单独的CPT表现出显着更高的抗癌活性，证明了CMD与CPT的协同治疗作用。综上所述，我们认为CMD纳米颗粒作为肉桂醛的聚合前药和药物载体在抗癌治疗中具有巨大的潜力。CMD纳米颗粒诱导酸触发的ROS生成，从而诱导凋亡性细胞死亡。喜树碱（CPT）被用作模型药物，以研究CMD纳米颗粒作为药物载体的潜力，并评估与CMD纳米颗粒的协同抗癌作用。在小鼠异种移植模型的研究中，负载CPT的CMD纳米颗粒比单独的空CMD纳米颗粒和单独的CPT表现出显着更高的抗癌活性，证明了CMD与CPT的协同治疗作用。综上所述，我们认为CMD纳米颗粒作为肉桂醛的聚合前药和药物载体在抗癌治疗中具有巨大的潜力。CMD纳米颗粒诱导酸触发的ROS生成，从而诱导凋亡性细胞死亡。喜树碱（CPT）被用作模型药物，以研究CMD纳米颗粒作为药物载体的潜力，并评估与CMD纳米颗粒的协同抗癌作用。在小鼠异种移植模型的研究中，负载CPT的CMD纳米颗粒比单独的空CMD纳米颗粒和单独的CPT表现出显着更高的抗癌活性，证明了CMD与CPT的协同治疗作用。综上所述，我们认为CMD纳米颗粒作为肉桂醛的聚合前药和药物载体在抗癌治疗中具有巨大的潜力。喜树碱（CPT）被用作模型药物，以研究CMD纳米颗粒作为药物载体的潜力，并评估与CMD纳米颗粒的协同抗癌作用。在小鼠异种移植模型的研究中，负载CPT的CMD纳米颗粒比单独的空CMD纳米颗粒和单独的CPT表现出显着更高的抗癌活性，证明了CMD与CPT的协同治疗作用。综上所述，我们认为CMD纳米颗粒作为肉桂醛的聚合前药和药物载体在抗癌治疗中具有巨大的潜力。喜树碱（CPT）被用作模型药物，以研究CMD纳米颗粒作为药物载体的潜力，并评估与CMD纳米颗粒的协同抗癌作用。在小鼠异种移植模型的研究中，负载CPT的CMD纳米颗粒比单独的空CMD纳米颗粒和单独的CPT表现出显着更高的抗癌活性，证明了CMD与CPT的协同治疗作用。综上所述，我们认为CMD纳米颗粒作为肉桂醛的聚合前药和药物载体在抗癌治疗中具有巨大的潜力。